A
ACRS
Aclaris Therapeutics Inc
5.62
+0.13+2.37%Pre Market: 5.41 -0.21 -3.74%07:21 07/08 EDT
OPEN/PREV CLOSE5.48/5.49
TODAY RANGE5.37-5.76
VOL4
MARKET CAP784.91M
52 WEEK RANGE1.435-5.76
AVG VOL (3M)1.55M
% TURNOVER0.99%
TURNOVER0
P/E (TTM)-10.0286
% RANGE7.01%
EPS(TTM)-0.5604
P/E(FORWARD)-8.5802
P/B5.46
BVPS1.029
DIVIDEND--
P/S86.59
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP739.30M
SHARES OUTSTANDING139.66M
NEXT EARNINGS08/05-08/10
FREE FLOAT131.55M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·5d ago
These low-priced stocks are flashing overbought signals
Benzinga·06/30 21:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga·06/22 12:02
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
NASDAQ·06/20 13:20
3 Penny Stocks Under $5 Backed by Real Revenue Growth
TipRanks·06/16 18:40
Aclaris Therapeutics management to meet with Oppenheimer
TipRanks·06/04 21:25
Aclaris Stockholders Approve Directors, Pay and Auditor
Benzinga·06/03 13:13
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday
Dow Jones·06/02 18:34
Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital
Dow Jones·06/02 18:34
Aclaris Therapeutics Initiated at Outperform by LifeSci Capital
TipRanks·06/02 00:35
Aclaris Therapeutics initiated with an Outperform at LifeSci Capital
TipRanks·05/11 11:55
Aclaris Therapeutics (ACRS) Gets a Buy from Piper Sandler
TipRanks·05/11 11:52
Guggenheim Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
Same Industry
Name/Symbol
Change%
Price